AIM ImmunoTech Inc (AIM)
0.28
+0.01
(+3.70%)
USD |
NYAM |
Sep 27, 16:00
0.2799
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech SG&A Expense (Annual): 21.14M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 21.14M |
| December 31, 2022 | 13.07M |
| December 31, 2021 | 8.672M |
| December 31, 2020 | 8.654M |
| December 31, 2019 | 7.039M |
| December 31, 2018 | 6.201M |
| December 31, 2017 | 6.572M |
| December 31, 2016 | 7.681M |
| December 31, 2015 | 7.147M |
| December 31, 2014 | 9.057M |
| December 31, 2013 | 7.723M |
| December 31, 2012 | 9.056M |
| December 31, 2011 | 6.691M |
| December 31, 2010 | 7.568M |
| December 31, 2009 | 5.796M |
| Date | Value |
|---|---|
| December 31, 2008 | 6.478M |
| December 31, 2007 | 8.974M |
| December 31, 2006 | 8.225M |
| December 31, 2005 | 5.389M |
| December 31, 2004 | 6.164M |
| December 31, 2003 | 4.257M |
| December 31, 2002 | 2.015M |
| December 31, 2001 | 3.412M |
| December 31, 2000 | 3.695M |
| December 31, 1999 | 8.721M |
| December 31, 1998 | 3.00M |
| December 31, 1997 | 3.50M |
| December 31, 1996 | 3.00M |
| December 31, 1995 | 4.00M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.039M
Minimum
2019
21.14M
Maximum
2023
11.72M
Average
8.672M
Median
2021
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Protalix BioTherapeutics Inc | 14.96M |
| Electromed Inc | 34.49M |
| Xtant Medical Holdings Inc | 64.29M |
| Armata Pharmaceuticals Inc | 11.65M |